Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel
Oscar Arrieta, Pablo Anaya, Vicente Morales-Oyarvide, Laura Alejandra Ramírez-Tirado, Ana C. Polanco
| Year of publication: |
September 2016
|
|---|---|
| Authors: | Arrieta, Oscar ; Anaya, Pablo ; Morales-Oyarvide, Vicente ; Ramírez-Tirado, Laura Alejandra ; Polanco, Ana C. |
| Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 17.2016, 7, p. 855-863
|
| Subject: | Cost-benefit analysis | Mutation | Carcinoma | Non-small-cell lung | Health policy | Developing countries | Kosten-Nutzen-Analyse | Krebskrankheit | Cancer | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Entwicklungsländer | Theorie | Theory | Gesundheitspolitik | Patienten | Patients | Gesundheitswesen | Health care system |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-015-0726-5 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10011654791